At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 79 enrolled
Drug / intervention
QAB149 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blind, Single-dose Study to Assess the Effect of the QAB149 and NVA237 Combination Versus QAB149 Alone on Inspiratory Capacity in Patients With Moderate or Severe COPD.
In Brief
A Phase 3 clinical trial evaluating QAB149, Placebo, and 1 other intervention for Chronic Obstructive Pulmonary Disease: COPD. Completed, enrolled 79 participants across 11 sites.
Detailed Summary
The study purpose is to evaluate the effect of QAB149 * NVA237 vs. QAB149 on static lung hyperinflation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSwitzerland
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 2012
Enrollment StartNov 2012
Primary CompletionJun 2014
TodayJul 2026
First PostedOct 4, 2012
Enrollment StartNov 1, 2012
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 13.7 years ago
Interventions
QAB149drug
Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
Placebodrug
Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
NVA237drug
Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI